1 – 10 of 29
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Cost-effectiveness analysis of (accelerated) pre-operative versus (conventional) post-operative radiotherapy for patients with oral cavity cancer in Sweden
(
- Contribution to journal › Article
-
Mark
Accuracy of gross tumour volume delineation with [68Ga]-PSMA-PET compared to histopathology for high-risk prostate cancer
(
- Contribution to journal › Article
- 2022
-
Mark
Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy
(
- Contribution to journal › Article
-
Mark
Results from a prospective, randomised study on (accelerated) preoperative versus (conventional) postoperative radiotherapy in treatment of patients with resectable squamous cell carcinoma of the oral cavity – The ARTSCAN 2 study
(
- Contribution to journal › Article
- 2021
-
Mark
ARTSCAN III : A randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer
(
- Contribution to journal › Article
-
Mark
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC) : patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
(
- Contribution to journal › Article
- 2020
-
Mark
Altered fractionation diminishes importance of tumor volume in oropharyngeal cancer : Subgroup analysis of ARTSCAN-trial
(
- Contribution to journal › Article
- 2019
-
Mark
Basic concepts and applications of functional magnetic resonance imaging for radiotherapy of prostate cancer
(
- Contribution to journal › Scientific review
-
Mark
Initial experience with introducing national Swedish guidelines for CT- and MRI-based delineation of organs at risk in radiotherapy
(
- Contribution to journal › Article
-
Mark
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer : 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
(
- Contribution to journal › Article